UBS Group’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $2.96M | Buy |
|
|||||
|
2025
Q2 | $721K | Sell |
|
|||||
|
2025
Q1 | $631K | Buy |
|
|||||
|
2024
Q4 | $901K | Buy |
|
|||||
|
2024
Q3 | $1.23M | Sell |
|
|||||
|
2024
Q2 | $1.51M | Sell |
|
|||||
|
2024
Q1 | $3.65M | Buy |
|
|||||
|
2023
Q4 | $2.29M | Buy |
|
|||||
|
2023
Q3 | $799K | Buy |
|
|||||
|
2023
Q2 | $488K | Sell |
|
|||||
|
2023
Q1 | $988K | Sell |
|
|||||
|
2022
Q4 | $1.44M | Buy |
|
|||||
|
2022
Q3 | $52K | Sell |
|
|||||
|
2022
Q2 | $580K | Sell |
|
|||||
|
2022
Q1 | $5.45M | Buy |
|
|||||
|
2021
Q4 | $3.67M | Buy |
|
|||||
|
2021
Q3 | $4.29M | Buy |
|
|||||
|
2021
Q2 | $1.15M | Sell |
|
|||||
|
2021
Q1 | $1.77M | Buy |
|
|||||
|
2020
Q4 | $1.22M | Buy |
|
|||||
|
2020
Q3 | $597K | Sell |
|
|||||
|
2020
Q2 | $743K | Buy |
|
|||||
|
2020
Q1 | $3K | Sell |
|
|||||
|
2019
Q4 | $6K | Buy |
|
|||||
|
2019
Q3 | – | Sell |
|
|||||
|
2019
Q2 | $28K | Buy |
|
|||||
|
2019
Q1 | – | Sell |
|
|||||
|
2018
Q4 | $6K | Sell |
|
|||||
|
2018
Q3 | $22K | Buy |
|
|||||
|
2018
Q2 | – | Sell |
|
|||||
|
2018
Q1 | $10K | Buy |
|
|||||
|
2017
Q4 | $9K | Buy |
|
|||||
|
2017
Q3 | $7K | Buy |
|
|||||
|
2017
Q2 | – | Sell |
|
|||||
|
2017
Q1 | $1K | Buy |
|
|||||
|
2016
Q4 | – | Sell |
|
|||||
|
2016
Q3 | $17K | Buy |
|
|||||
|
2016
Q2 | $30K | Buy |
|
|||||
|
2016
Q1 | $8K | Sell |
|
|||||
|
2015
Q4 | $19K | Buy |
|
|||||
|
2015
Q3 | $2K | Sell |
|
|||||
|
2015
Q2 | $52K | Buy |
|
|||||
|
2015
Q1 | $21K | Buy |
|
|||||
|
2014
Q4 | $1K | Buy |
|